Serum Institute of India (SII) | Zee News

Advertisement

NewsSerum Institute of India (SII)

Serum Institute of India (SII) News

23 Nov 2021

Serum Institute of India to start Covishield supply to COVAX countries

"The first consignment from the Pune facility of Serum Institute of India was scheduled to leave for Nepal today. However, due to some reason, it has been delayed by two to three days," said SII sources.

14 Aug 2021

SII chairman Cyrus Poonawalla warns against mixing of vaccine, here’s why

"I am against the mixing of two different vaccines. There is no need to mix two different vaccines," said Cyrus Poonawalla. He further stated that the efficacy of this approach has not been proven in field trials involving thousands of participants.

06 Aug 2021

Hope to launch Covovax vaccine for adults in October this year: SII CEO

Poonawala said he is hopeful that for adults Covovax will be launched in October, depending on DCGI approvals. It will be a two-dose vaccine and the price will be decided at the time of launch, he added. Poonawalla met Home Minister Amit Shah in Parliament and the meeting between the two lasted for 30 minutes.

COVID-19 vaccine

18 Jul 2021

Good news: SII CEO Poonawalla as 16 European countries recognise Covishield

On Saturday, France lifted travel restrictions for fully vaccinated travellers. Indian government has been pushing European Union member countries to recognise both Covishield and Covaxin in order to ease travel for the people

COVID-19 vaccine

17 Jul 2021

No application received for EU authorisation of Covishield: EMA

EMA has approved only four vaccines namely, Comirnaty of Pfizer/BioNTech, Moderna's Spikevax, Vaxzervria by AstraZeneca-Oxford and Johnson & Johnson's Janssen. The SII’s CEO Adar Poonawalla had earlier said that the company is confident of receiving approval from the EMA.

COVID-19 vaccine

28 Jun 2021

Serum Institute CEO Adar Poonawalla assures help to Indians for this reason

The CEO of Serum Institute of India (SII) Adar Poonawalla on Monday assured the people of the nation that the issue is being with at the highest level. The statement comes amid the reports of the European Union’s new concept of Green Pass is doing rounds in media.

COVID-19 vaccine

18 Jun 2021

SII to launch second COVID-19 vaccine Covavax by September: Report

Serum Institute plans to start clinical trials of the Novavax shot for children in July. ANI reported. "This vaccine is very safe and highly effective. It`ll be produced in India," Centre said about Covavax.

COVID-19 vaccine

31 May 2021

India aims to procure 20-25 crore COVID-19 vaccine by July end: Report

The Centre on Sunday (May 30, 2021) said that it targets to procure 20-25 crore coronavirus vaccine doses by July-end, and 30 crore doses in August-September. The SII officials in a recent letter addressed to Home Minister Amit Shah said that their employees have been working round the clock in spite of the challenges that the pandemic presents.

22 May 2021

Centre widened COVID vaccination drive without considering stock: SII

The executive director of SII, Suresh Jadhav on Friday alleged that the central government widened the COVID-19 vaccination drive without into account the available stock of vaccines. "India should have followed the WHO guidelines and prioritised vaccination accordingly," said Suresh Jadhav.

Adar Poonawalla

18 May 2021

It would take 2-3 years for entire world population to get fully vaccinated

Poonawalla said that it will take another two to three years for the entire world population to get fully vaccinated He also said that "a vaccination drive for such a large population cannot be completed within 2-3 months" The serum has delivered more than 200 million doses

Adar Poonawalla

18 May 2021

Adar Poonawalla exits Panacea Biotec, sells entire stake for Rs 118 crore

As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share.

14 May 2021

Hyderabad based Bharat Biotech to start producing coronavirus vaccines in Pune

Bharat Biotech International Ltd will soon start manufacturing Covid-19 vaccines in Pune The state would also request the BBIL to give priority to supply vaccines to Maharashtra after fulfilling its commitments to the Centre Currently, the government-owned BBIL is one of the two Indian companies manufacturing the Covaxin and Covishield vaccines

30 Apr 2021

Bill Gates says COVID vaccine formula should not be shared with India

Bill Gates in an interview with Sky News was asked if it would be possible to change the intellectual property law Bill Gates refused to share vaccine formula Bill Gates faces heat from global community for this statement

25 Mar 2021

India delays big exports of AstraZeneca vaccine as Covid-19 cases surge

COVAX has so far received 17.7 million AstraZeneca doses from the SII The SII has already delayed shipments of the AstraZeneca drug to Brazil, Britain, Morocco and Saudi Arabia With 11.7 million cases, India has reported the highest number of coronavirus infections after the United States and Brazil

22 Mar 2021

Centre asks states, UTs to increase gap between two doses of Covishield

The Centre also clarified that the above instruction is only for Covishield and not Bharat Biotech’s Covaxin. "This decision of revised time interval between two doses is applicable ONLY to COVISHIELD and NOT to COVAXIN Vaccine," the government stated.

Nepal COVID-19 vaccine

21 Feb 2021

COVID-19: Nepal to begin inoculation drive as it receives Indian vaccines

Nepal has expedited preparations to start inoculating elderly and most vulnerable age groups from next month as it received a batch of COVID-19 vaccines purchased from India. A batch of one million Covishield vaccines developed by the Serum Institute of India (SII) was delivered on Sunday (February 21) via an Air India flight.

03 Aug 2020

DCGI nod to SII for phase 2 and 3 human clinical trials of COVID-19 vaccine

The approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night. Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa. The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25.

Loading...

NEWS ON ONE CLICK